These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16306305)

  • 1. Alterations in lipid profiles in HIV-infected patients treated with protease inhibitor therapy are not influenced by diet.
    Wanke C; Gerrior J; Hendricks K; McNamara J; Schaefer E
    Nutr Clin Pract; 2005 Dec; 20(6):668-73. PubMed ID: 16306305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients.
    Asztalos BF; Schaefer EJ; Horvath KV; Cox CE; Skinner S; Gerrior J; Gorbach SL; Wanke C
    Atherosclerosis; 2006 Jan; 184(1):72-7. PubMed ID: 15935358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HIV infection and HAART on serum lipids in men.
    Riddler SA; Smit E; Cole SR; Li R; Chmiel JS; Dobs A; Palella F; Visscher B; Evans R; Kingsley LA
    JAMA; 2003 Jun; 289(22):2978-82. PubMed ID: 12799406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
    Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
    HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
    Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.
    Levy AR; McCandless L; Harrigan PR; Hogg RS; Bondy G; Iloeje UH; Mukherjee J; Montaner JS
    Lipids Health Dis; 2005 Feb; 4():4. PubMed ID: 15705191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
    Muhammad S; Sani MU; Okeahialam BN
    Ann Afr Med; 2013; 12(1):24-8. PubMed ID: 23480991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
    Hiransuthikul N; Hiransuthikul P; Kanasook Y
    Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial.
    Lazzaretti RK; Kuhmmer R; Sprinz E; Polanczyk CA; Ribeiro JP
    J Am Coll Cardiol; 2012 Mar; 59(11):979-88. PubMed ID: 22402068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
    Blick G; Greiger-Zanlungo P; Gretz S; Han J; Dupree D; Garton T; Yau LH; Wine BC; Pakes GE;
    Int J STD AIDS; 2012 Mar; 23(3):e18-22. PubMed ID: 22581890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.
    Langat A; Benki-Nugent S; Wamalwa D; Tapia K; Ngugi E; Diener L; Richardson BA; Melvin A; John-Stewart GC
    Pediatr Infect Dis J; 2013 Jul; 32(7):e298-304. PubMed ID: 23385950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
    Koppel K; Bratt G; Eriksson M; Sandström E
    Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.